Compare Quest Diagnostics Inc (DGX) vs Kaltura Inc (KLTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Kaltura Inc — how do they compare? Quest Diagnostics Inc trades at $230.17 (market cap $25.48B), while Kaltura Inc trades at $1.32 (market cap $199.08M). The key difference: Quest Diagnostics Inc is far larger — about 128× Kaltura Inc's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Kaltura Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Kaltura Inc for 21 Days on average.
| DGX | KLTR | |
|---|---|---|
Market Cap | $25.48B | $199.08M |
Volume | 941,866 | 175,927 |
Sector | Health | Technology |
52-Week High | $247.45 | $1.89 |
52-Week Low | $173.49 | $1.08 |
Typical Hold Time | 56 Days | 21 Days |
Enterprise Value | $31.23B | $211.29M |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $227.00, down 0.64% with a bearish technical signal. The company shows strong fundamentals with three consecutive quarterly earnings beats and revenue growth from $9.9B in 2024 to $11.0B in 2025. Recent developments include positive clinical study results and a new Apple Health integration, though Medicare reimbursement cuts pose headwinds. The stock trades near support at $226 with oversold RSI readings suggesting potential for near-term bounce.
DGX presents a mixed outlook with solid execution offset by regulatory risks. The 10% upside to consensus price target of $250 offers opportunity, but Medicare payment reductions and rising debt levels require monitoring. Recent earnings momentum and strategic partnerships support growth, making DGX suitable for investors comfortable with healthcare sector volatility.
KLTR trades at $1.33, up 3.91% today, showing positive momentum despite a bearish technical signal. The company demonstrates improving fundamentals with revenue stabilizing around $181M and net losses narrowing from -$68M in 2022 to -$12M in 2025. Recent earnings beats and industry recognition for AI-powered video platforms provide optimism, though negative ROE (-134.25%) and high debt levels remain concerns.
KLTR presents a turnaround story with improving financials and strong AI positioning, but faces significant execution risks. The stock offers speculative upside if the company can achieve profitability, though current valuation metrics (P/S 1.08, EV/EBITDA 271.59) reflect market skepticism about near-term earnings potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Kaltura Inc
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments: (i) Enterprise, Education, and Technology (EE&T)
Read more on KLTR →
